| Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas I Langer, P Vertongen, J Perret, J Fontaine, G Atassi, P Robberecht Medical and pediatric oncology 34 (6), 386-393, 2000 | 109 | 2000 |
| Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction RM Solano, I Langer, J Perret, P Vertongen, MG Juarranz, P Robberecht, ... Journal of Biological Chemistry 276 (2), 1084-1088, 2001 | 85 | 2001 |
| Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins G Berkenboom, I Langer, Y Carpentier, K Grosfils, J Fontaine Hypertension 30 (3), 371-376, 1997 | 81 | 1997 |
| Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors H Malonne, I Langer, R Kiss, G Atassi Clinical & experimental metastasis 17 (1), 1-18, 1999 | 72 | 1999 |
| Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor X Peyrassol, T Laeremans, M Gouwy, V Lahura, M Debulpaep, ... The Journal of Immunology 196 (6), 2893-2901, 2016 | 65 | 2016 |
| Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheres S Marquette, C Peerboom, A Yates, L Denis, I Langer, K Amighi, J Goole International journal of pharmaceutics 470 (1-2), 41-50, 2014 | 53 | 2014 |
| Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin M Foucaud, E Archer-Lahlou, E Marco, IG Tikhonova, B Maigret, ... Regulatory peptides 145 (1-3), 17-23, 2008 | 50 | 2008 |
| Mechanism of activation of a G protein-coupled receptor, the human cholecystokinin-2 receptor E Marco, M Foucaud, I Langer, C Escrieut, IG Tikhonova, D Fourmy Journal of biological chemistry 282 (39), 28779-28790, 2007 | 45 | 2007 |
| Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies. I Langer Frontiers in endocrinology 3, 129, 2012 | 43 | 2012 |
| Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy R Rosière, M Van Woensel, V Mathieu, I Langer, T Mathivet, ... International journal of pharmaceutics 501 (1-2), 148-159, 2016 | 42 | 2016 |
| Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G … I Langer, P Robberecht Biochemical Society Transactions 35 (4), 724-728, 2007 | 40 | 2007 |
| Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin … J Perret, M Van Craenenbroeck, I Langer, P Vertongen, F Grégoire, ... Biochemical journal 362 (2), 389-394, 2002 | 38 | 2002 |
| Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling C Langlet, I Langer, P Vertongen, N Gaspard, JM Vanderwinden, ... Journal of Biological Chemistry 280 (30), 28034-28043, 2005 | 37 | 2005 |
| Vasoactive intestinal peptide (VIP) stimulates [Ca 2+] i and cyclic AMPin CHO cells expressing Gα16 I Langer, J Perret, P Vertongen, M Waelbroeck, P Robberecht Cell calcium 30 (4), 229-234, 2001 | 34 | 2001 |
| Evidence that interaction between conserved residues in transmembrane helices 2, 3, and 7 are crucial for human VPAC1 receptor activation AO Chugunov, J Simms, DR Poyner, Y Dehouck, M Rooman, D Gilis, ... Molecular pharmacology 78 (3), 394-401, 2010 | 33 | 2010 |
| Evidence that interspecies polymorphism in the human and rat cholecystokinin receptor-2 affects structure of the binding site for the endogenous agonist cholecystokinin I Langer, IG Tikhonova, MA Travers, E Archer-Lahlou, C Escrieut, ... Journal of Biological Chemistry 280 (23), 22198-22204, 2005 | 33 | 2005 |
| Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC 1 receptor impair VIP-stimulated [Ca 2+] i increase but not adenylate cyclase … I Langer, P Robberecht Cellular signalling 17 (1), 17-24, 2005 | 30 | 2005 |
| Signal transduction by VIP and PACAP receptors I Langer, J Jeandriens, A Couvineau, S Sanmukh, D Latek Biomedicines 10 (2), 406, 2022 | 28 | 2022 |
| Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor I Langer, C Langlet, P Robberecht Journal of molecular endocrinology 34 (2), 405-414, 2005 | 25 | 2005 |
| Partial agonism, neutral antagonism, and inverse agonism at the human wild-type and constitutively active cholecystokinin-2 receptors M Foucaud, IG Tikhonova, I Langer, C Escrieut, M Dufresne, C Seva, ... Molecular pharmacology 69 (3), 680-690, 2006 | 24 | 2006 |
